Klin Farmakol Farm. 2008;22(1):18-22

ALFIMEPRASE - A NOVEL, DIRECT-ACTING FIBRINOLYTIC AGENT

Jozef Kolář
Ústav aplikované farmacie, Farmaceutická fakulta VFU, Brno

This article describes the continuing investigation of alfimeprase, a novel direct-acting thrombolytic agent for its indications - the treatment of acute peripheral arterial occlusion, stroke, and catheter occlusion. Alfimeprase dissolves blood clots faster than current therapies, degrades fibrin directly.

Keywords: Key words: alfimeprase, fibrinolytic agent, thrombolysis.

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolář J. ALFIMEPRASE - A NOVEL, DIRECT-ACTING FIBRINOLYTIC AGENT. Klin Farmakol Farm. 2008;22(1):18-22.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Deitcher SR, Toombs ChF. Non-Clinical and Clinical Characterization of a Novel Acting Thrombolytic: Alfimeprase. Pathophysiol. Haemost. Thromb., 2005; 34: 215-220. Go to original source... Go to PubMed...
    2. Gandalovičová J. Současné trendy trombolytické terapie u akutních koronárních syndromů. Interní medicína pro praxi 2002; 1: 29-32.
    3. Ouriel K, Cynamon J, Weaver FA, Dardik H, Akers D, Blebea J, Gruneiro L, Toombs ChF, Wang-Clow F, Mohler M, Pena L, Ching-Yi Wan, Deitcher SR. A Phase I Trial of Alfimeprase for Peripheral Arterial Thrombolysis. J. Vasc. Interv. Radiol., 2005; 16: 1075-1083. Go to original source... Go to PubMed...
    4. Malý J, Widimský J. Trombolytická léčba plicní embolie. http://www.hrubaskala.net/mini_soubory/04/290504_3.pdf.
    5. Moll S, Kenyon P, Bertoli L, DeMaio J, Homesley H, Deitcher SR. Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access Devices. J. Clin. Oncol., 2006; 24: 3056-3060. Go to original source... Go to PubMed...
    6. Nikhil Sikri, Amit Bardia: A History of Streptokinase Use in Acute Myocardial Infarction. Tex. Heart Inst. J., 2007; 34: 318-327.
    7. Deitcher SR, Begelman S. Alfimeprase - a Novel, Direct-Acting Fibrinolytic Agent in Acute Peripheral Arterial Occlusion: Report of a Phase 2, Multi-center, Open-Label, Dose-Defining Study (NAPA-1).
    8. Deitcher SR, Moll S, Kenyon P, Swischuk P, Bertoli L, DeMaio J, Homesley H, Pe a L. Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters: A Phase 2, Multi-Center, Randomized, Double-Blind Study (NuCath).
    9. Moll S, Gabrail N, Buchanan J, Hirmand M, Levy M, Zitnik R. Safety and Efficacy of Alfimeprase in Subjects with Occluded Central Venous Access Devices: The SONOMA-2 Study.
    10. Ting-Ting Hong, Jinbao Huang, Lucchesi BR. Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. Alfimeprase. Amer. J. Physiol. Heart Circ. Physiol., 2006; 290: H959-H967. Go to original source... Go to PubMed...
    11. Novotný J. Nové antitrombotické léky. Ambulantná terapia 2007; 5: 18-20.
    12. Janoušek S. Trombolytická (fibrinolytická) léčba akutního infarktu myokardu. Kardiolog. Forum 2006; 4: 66-80.
    13. Bellucci N. Significant milestone. Drugs in development. R&D Directions 2006; 12: 4.
    14. Borovanský A, Csöllei J. Farmaceutická chemie (Farmakochemie). IV. Léčiva s účinkem na kardiovaskulární systém. FaF VFU Brno.
    15. Nuvelo drops alfimperase for arterial occlusion. Scrip 2008, č. 3333, s. 24.
    16. ##
    17. Studie: Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion (NAPA-3)
    18. Studie: Phase 2, Multicenter, Open-Label, Two-Stage Study to Evaluate the Safety and Efficacy of Intra-Arterial Catheter-Directed Alfimperase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke (CARNEROS-1)
    19. Studie: Phase 3, Multicenter, Multinational, Open-Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects With Occluded Central Venous Access Devices (SONOMA-3: Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase)
    20. Studie: Phase 3, Multicenter, Multi-National, Randomized, Partial Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion
    21. Studie: A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion.
    22. Studie: Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Occluded Central Venous Access Devices
    23. Studie: A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.